Pharmaceutical companies today

Orange and white medication pill pharmaceutical

The COVID-19 pandemic has given a strong impetus to the development of many pharmaceutical companies. Consider who has succeeded in their development more than others and which companies should be adopted.

Anti-covid cocktail drives record revenue for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is an American biotechnology company founded in 1988. The most commercially successful product of the company is the anti-covid “cocktail” of REGEN-COV antibodies, which US ex-President Donald Trump used to treat the coronavirus.

As a representative of Regeneron said earlier, the US government has already purchased up to 1.5 million doses of the drug, and it is provided free of charge to patients. In the first half of 2021, Regeneron sold REGEN-COV doses totaling $ 2.85 billion (37.2% of total revenue) without a full-fledged regulatory license. REGN shares have gained 69.27% ​​since December 31, 2019, while the S&P 500 is up 36.2%, and the industry average S&P 500 Healthcare is up 32.05%.

The stock is recommended to buy with a target price of $ 755.02, which implies a 15% upside potential.

Axsome Therapeutics shares jump 19%

Axsome Therapeutics, a biotech company that develops new treatments for central nervous system diseases, jumped 19.06% in a New York premarket.

The company said on Monday that it had received a response from the US Food and Drug Administration (FDA) that a new application for a depressive disorder drug (AXS-05) would not be completed by the target date of August 22, 2021.

However, the FDA did not request additional information from Axsome; the application is ongoing.

Shares closed 8.29% higher on Friday.

Trillium Shares soar 190% after news of merger with Pfizer

Trillium and Pfizer announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, which develops innovative cancer treatments. Under the terms of the agreement, Pfizer will acquire all outstanding Trillium shares not yet owned by Pfizer for $ 2.26 billion, or $ 18.50 per share.

This represents a 118% premium to Trillium’s 60-day weighted average share price.

Trillium possesses the only known targeting molecule, SIRPα – CD47, with clinically significant responses to monotherapy and a solid basis for combination therapy, supported by preclinical data with diverse therapeutic agents. With Pfizer’s global reach and capabilities, programs will move faster to patients.